Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

The S&P 500 fell 0.8% on Monday, Feb. 3, as investors reacted to tariffs on major U.S. trading partners while awaiting key earnings and labor market data.

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.